Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May;11(5):706-710.
doi: 10.21037/tlcr-22-268.

Liquid biopsies come of age in lung cancer

Petros Christopoulos  1   2
Affiliations
Editorial

Liquid biopsies come of age in lung cancer

Petros Christopoulos. Transl Lung Cancer Res. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-268/coif). The author declares research funding from AstraZeneca, Amgen, Merck, Novartis, Roche, and Takeda; speaker’s honoraria from AstraZeneca, Novartis, Roche, Takeda; support for attending meetings from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Janssen, Novartis, Takeda; and personal fees for participating to advisory boards from Boehringer Ingelheim, Chugai, Pfizer and Roche; all outside the submitted work. The author has no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
Emerging applications of liquid biopsies in thoracic oncology. From the identification of actionable drivers at initial diagnosis of lung cancer, as described by Low et al. and other studies (1,5), to the profiling of acquired resistance at the time of disease progression (12,14), longitudinal monitoring (15,24) with prediction of durable benefit under targeted therapies (14) and immunotherapy (20,22), detection of minimal residual disease (MRD) after surgery (20) or chemoradiation (22), and the ongoing trials of cancer screening in high-risk populations, liquid biopsies master progressively difficult tasks in thoracic oncology, which is becoming a model field for the successful clinical application of novel molecular tools.
See this image and copyright information in PMC

Comment on

References

    1. Low SK, Ariyasu R, Uchibori K, et al. Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer. Transl Lung Cancer Res 2022;11:711-21. 10.21037/tlcr-21-981 - DOI - PMC - PubMed
    1. Meric-Bernstam F, Brusco L, Shaw K, et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol 2015;33:2753-62. 10.1200/JCO.2014.60.4165 - DOI - PMC - PubMed
    1. Robert NJ, Nwokeji ED, Espirito JL, et al. Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices. J Clin Oncol 2021;39:9004. 10.1200/JCO.2021.39.15_suppl.9004 - DOI
    1. Griesinger F, Eberhardt W, Nusch A, et al. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer 2021;152:174-84. 10.1016/j.lungcan.2020.10.012 - DOI - PubMed
    1. Leighl NB, Page RD, Raymond VM, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res 2019;25:4691-700. 10.1158/1078-0432.CCR-19-0624 - DOI - PubMed

Publication types